Table 4

Medication costs among patients with prostate cancer and bone metastasis in Beijing from 2011 to 2014 (per patient per year)

Year (N)2011 (n=322)2012 (n=459)2013 (n=561)2014 (n=611)
MedicationN (%)Mean; median
(Q1, Q3)
N (%)Mean; median
(Q1, Q3)
N (%)Mean; median
(Q1, Q3)
N (%)Mean; median
(Q1, Q3)
Western medication322 (100.0%)6736.8; 4172.8
(1909.6, 9381.7)
458 (99.8%)7704.2; 4876.1
(2605.1, 10 421.6)
558 (99.5%)7197.4; 4586.0
(2192.8, 9655.7)
610 (99.8%)7057.8; 4789.3
(2229.7, 9037.8)
Radiotherapy16 (5.0%)417.2; 1.0
(0.7, 30.2)
23 (5.0%)305.2; 2.8
(0.8, 124.9)
12 (2.1%)212.0; 0.9
(0.6, 6.9)
23 (3.8%)220.7; 5.5
(1.2, 16.1)
Chemotherapy56 (17.4%)84.6; 16.1
(4.4, 58.6)
94 (20.5%)164.1; 23.8
(6.6, 71.1)
118 (21.0%)92.8; 23.6
(6.6, 54.4)
124 (20.3%)89.7; 21.8
(7.4, 83.7)
Endocrine therapy277 (86.0%)1304.1; 818.6
(3572.4, 24 677.1)
399 (86.9%)1512.8; 1070.4
(344.6, 2048.9)
472 (84.1%)1505.8; 1039.8
(364.3, 2117.3)
500 (81.8%)1481.0; 1036.7
(432.8, 1980.2)
Bisphosphonates216 (67.1%)335.9; 64.4
(7.9, 425.3)
282 (61.4%)433.3; 114.7
(7.2, 564.5)
300 (53.5%)433.9; 155.0
(13.0, 544.9)
294 (48.1%)449.2; 180.5
(11.8, 641.0)
Traditional Chinese medication310 (96.3%)1623.1; 783.0
(244.4, 2099.6)
447 (97.4%)1902.6; 1122.2
(360.3, 2600.5)
541 (96.4%)1886.8; 1032.9
(330.6, 2584.3)
591 (96.7%)1858.1; 1067.0
(362.6, 2548.0)
Total322 (100.0%)8299.3; 5076.5
(2335.7, 11 191.3)
458 (99.8%)9561.2; 6059.6
(3255.0, 12 933.9)
558 (99.5%)9026.8; 5693.6
(2817.8, 12 784.8)
610 (99.8%)8858.0; 5956.7
(2875.3, 11 413.6)
  • Q1 = 25% quartile/Q3 = 75% quartile.